Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference
March 16, 2017 16:05 ET
|
Curis, Inc
LEXINGTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- March 16, 2017 - Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug...
Curis Reports Fourth Quarter and Year-End 2016 Financial Results
March 09, 2017 07:00 ET
|
Curis, Inc
-- Company Announces $45 million Debt Transaction with HealthCare Royalty Partners Secured with Future Erivedge® Royalty -- -- Management to host conference call today at 8:30 a.m. EST -- LEXINGTON,...
Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on March 9, 2017
March 07, 2017 07:05 ET
|
Curis, Inc
LEXINGTON, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis to Present at the Cowen and Company 37th Annual Health Care Conference
March 01, 2017 18:33 ET
|
Curis, Inc
LEXINGTON, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference
February 17, 2017 16:30 ET
|
Curis, Inc
LEXINGTON, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration
January 09, 2017 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 06, 2017 16:12 ET
|
Curis, Inc
LEXINGTON, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis Announces Full Approval of Roche’s Erivedge® in the European Union
November 28, 2016 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors
November 14, 2016 07:00 ET
|
Curis, Inc
LEXINGTON, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug...
Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170’s Phase 1 Trial at the SITC 2016 Conference
November 09, 2016 12:15 ET
|
Curis, Inc
LEXINGTON, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...